Decreased Muscle Mass Linked with Higher Toxicity, Poorer Prognosis Risk in Colon Cancer

Share this content:

the Cancer Therapy Advisor take:

Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in patients with stage 3 colon cancer, according to a recent study published in Supportive Care in Cancer.

Korean researchers led by Hee-Won Jung, MD, at the Seoul National University College of Medicine examined data on 229 patients with stage 3 colon cancer who received adjuvant oxaliplatin, 5-fluorouracil, and leucovorin chemotherapy from 2003 to 2010, measuring for effects of muscle mass on toxicity and survival. Median age was 61 years and 134 patients were male.

The researchers found that decrease in muscle mass was associated with increased toxicity in all grade 3/4 cancers in univariate and multivariate analyses.

In multivariate analysis alone, they found that an incremental decrease in muscle mass index increased the hazard of overall mortality.

The effect was further confirmed in subgroup analyses and it was further pronounced in patients who were older and obese.

Colon cancer: Adding cetuximab to chemotherapy
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in stage 3 colon cancer.
The purpose of this study was to elucidate the effect of decreased muscle mass on the toxicity and survival of patients with colon cancer treated with adjuvant chemotherapy after surgery.
READ FULL ARTICLE From Mdlinx

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters